Drug Profile

Research programme: immuno-oncology therapies - JAGUAHR Therapeutics

Latest Information Update: 09 Jan 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

09 Jan 2023 Preclinical trials in Solid tumours in Singapore (Bukwangpharm pipeline, January 2023)
24 Jun 2021 JAGUAHR Therapeutics plans to file an IND application in 2022
07 Oct 2019 ASLAN Pharmaceuticals and the Bukwang Pharmaceutical formed a joint venture company, JAGUAHR Therapeutics, to develop novel immuno-oncology therapies for cancer in Singapore

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com